Use of proton-pump inhibitors among adults: a Danish

Therapeutic Advances in Gastroenterology
9, 671-678
DOI: 10.1177/1756283x16650156

Citation Report

#	Article	IF	Citations
1	Effective and safe proton pump inhibitor therapy in acid-related diseases â€“ A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 2016, 14, 179.	2.3	300
2	Data Resource Profile: The Danish National Prescription Registry. International Journal of Epidemiology, 2017, 46, dyw213.	0.9	649
3	Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults. Drugs and Aging, 2017, 34, 265-287.	1.3	33
4	Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs. Clinical Therapeutics, 2017, 39, 404-427.e36.	1.1	7
5	Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology, 2017, 153, 702-710.	0.6	121
6	Any role for proton pump inhibitors in the relationship between new erosive oesophagitis and abdominal visceral fat?. European Journal of Gastroenterology and Hepatology, 2017, 29, 489.	0.8	0
7	Acid-suppressing therapies and subsite-specific risk of stomach cancer. British Journal of Cancer, 2017, 116, 1234-1238.	2.9	13
8	Transarterial embolization for hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2017, 29, 488-489.	0.8	2
9	Montelukast useâ€”a 19-year nationwide drug utilisation study. European Journal of Clinical Pharmacology, 2017, 73, 1297-1304.	0.8	7
10	Proton pump inhibitor use and risk of hip fractures among communityâ€dwelling persons with Alzheimer's diseaseâ€”a nested caseâ€control study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1135-1142.	1.9	24
11	The Association Between Proton Pump Inhibitor Use With Acute Kidney Injury and Chronic Kidney Disease. Journal of Clinical Gastroenterology, 2018, 52, 468-476.	1.1	20
12	Side Effects of Longâ€Term Proton Pump Inhibitor Use: A Review. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 114-121.	1.2	105
13	Early Discontinuation of Montelukast Treatment; A Danish Nationwide Utilization Study. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 78-83.	1.2	0
14	Lack of Association Between Proton Pump Inhibitor Use andÂCognitive Decline. Clinical Gastroenterology and Hepatology, 2018, 16, 681-689.	2.4	32
15	Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. Therapie, 2018, 73, 385-388.	0.6	14
16	Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?. American Journal of Gastroenterology, 2018, 113, 519-528.	0.2	39
17	Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clinical Gastroenterology and Hepatology, 2018, 16, 800-808.e7.	2.4	127
18	Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis. Therapie, 2018, 73, 273-281.	0.6	15

#	Article	IF	Citations
19	Deprescribing proton pump inhibitors: why, when and how. Medical Journal of Australia, 2018, 209, 436-438.	0.8	9
20	Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1534-1541.	2.2	16
21	Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS ONE, 2018, 13, e0204231.	1.1	41
22	Proton pump inhibitors are not associated with inflammatory myopathies: A case control study. Muscle and Nerve, 2018, 58, 855-857.	1.0	3
23	Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish caseâ€control study. Alimentary Pharmacology and Therapeutics, 2018, 48, 618-625.	1.9	38
24	Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481877794.	1.4	92
25	Use of proton pump inhibitors and risk of pancreatic cancer. Pharmacoepidemiology and Drug Safety, 2018, 27, 926-930.	0.9	16
26	Burden of drug use for gastrointestinal symptoms and functional gastrointestinal disorders in France: a national study using reimbursement data for 57 million inhabitants. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985379.	1.4	5
27	Treatment of newly-diagnosed gastroesophageal reflux disease: a nationwide register-based cohort study. Scandinavian Journal of Gastroenterology, 2019, 54, 830-837.	0.6	4
28	Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Journal of Bone and Mineral Research, 2019, 34, 2238-2245.	3.1	11
29	Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollingerâ€“Ellison Syndrome. International Journal of Molecular Sciences, 2019, 20, 5128.	1.8	24
30	Adverse Effects of Proton Pump Inhibitorsâ€”Evidence and Plausibility. International Journal of Molecular Sciences, 2019, 20, 5203.	1.8	92
31	Problems Associated with Deprescribing of Proton Pump Inhibitors. International Journal of Molecular Sciences, 2019, 20, 5469.	1.8	51
32	The Enterochromaffin-like [ECL] Cellâ€”Central in Gastric Physiology and Pathology. International Journal of Molecular Sciences, 2019, 20, 2444.	1.8	25
33	Prescribing of proton-pump inhibitors: auditing the management and reasons for prescribing in Danish general practice. Family Practice, 2019, 36, 758-764.	0.8	7
34	Association Between Acute Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses. JAMA Network Open, 2019, 2, e1916205.	2.8	35
35	Use of proton pump inhibitors among Danish children: A 16â€year registerâ€based nationwide study. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 704-710.	1.2	25
36	Risk of fall in patients taking proton pump inhibitors: a meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 115-121.	0.2	11

#	Article	IF	Citations
37	Low Prevalence of Suspected Barrettâ€™s Esophagus in Patients With Gastroesophageal Reflux Disease Without Alarm Symptoms. Clinical Gastroenterology and Hepatology, 2019, 17, 857-863.	2.4	16
38	A Study on the Status of Proton Pump Inhibitor Prescriptions Using Diagnosis Procedure Combination Data in Japan. Digestion, 2020, 101, 308-315.	1.2	7
39	Acid Suppressive Therapy. , 2020, , 18-31.		0
40	Systematic review with metaâ€analysis: the risks of proton pump inhibitors during pregnancy. Alimentary Pharmacology and Therapeutics, 2020, 51, 410-420.	1.9	37
41	Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. European Journal of Clinical Pharmacology, 2020, 76, 547-555.	0.8	8
42	Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. European Journal of Clinical Pharmacology, 2020, 76, 449-457.	0.8	66
43	Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. Journal of Gastroenterology, 2020, 55, 453-461.	2.3	28
44	Effect of proton pump inhibitors on Rubidium-82 gastric uptake using positron emission tomography myocardial perfusion imaging. Journal of Nuclear Cardiology, 2020, 27, 1443-1451.	1.4	5
45	Medication-related factors associated with proton pump inhibitor prescription beyond official guidelines in older adults. European Geriatric Medicine, 2020, 11, 1051-1061.	1.2	1
46	Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Frontiers in Pharmacology, 2020, 11, 552102.	1.6	14
47	Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia. BMJ Quality and Safety, 2020, 29, 365-373.	1.8	12
48	Incidence and Prevalence of Microscopic Colitis Between 2001 and 2016: A Danish Nationwide Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 1717-1723.	0.6	30
49	Time Trends in Healthcare Utilization Due to Self-Reported Functional Diseases of the Stomach. Digestive Diseases and Sciences, 2020, 65, 2824-2833.	1.1	3
50	Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?. Endocrine, 2020, 67, 281-290.	1.1	26
51	Gastric Corpus Mucosal Hyperplasia and Neuroendocrine Cell Hyperplasia, but not Spasmolytic Polypeptide-Expressing Metaplasia, Is Prevented by a Gastrin Receptor Antagonist in H+/K+ATPase Beta Subunit Knockout Mice. International Journal of Molecular Sciences, 2020, 21, 927.	1.8	1
52	Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013â€“2016. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482091374.	1.4	30
53	Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome. Sleep, 2021, 44, .	0.6	5
54	Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199892.	1.4	25

#	Article	IF	Citations
55	Reflux Symptoms: Functional and Structural Diseases and the Approach from the GI Specialist. Digestive Diseases, 2021, 39, 590-597.	0.8	0
56	When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterology, 2021, 8, e000563.	1.1	21
57	Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection. Clinical Infectious Diseases, 2021, 72, e1084-e1089.	2.9	25
58	Proton pump inhibitors and the risk of pancreatic cancer. Journal of Gastroenterology, 2021, 56, 295-296.	2.3	0
59	Proton-pump Inhibitors and the Risk of Dementia: A Systematic Review and Meta-analysis. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2021, 21, 135-143.	0.1	2
60	Diagnosis of <i>Helicobacter pylori</i> Infection by the Arrangement of Collecting Venules Using White Light Endoscopy: Evaluation of Interobserver Agreement. Digestive Diseases, 2022, 40, 376-384.	0.8	5
61	Proton-pump inhibitor use and risk of community-acquired pneumonia in congenital heart disease patients. International Journal of Cardiology Congenital Heart Disease, 2021, 4, 100152.	0.2	0
62	Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander?. Gastroenterology, 2021, 161, 1789-1791.	0.6	4
63	Proton pump inhibitors long term useâ€trends and patterns over 15â€‰years of a large health maintenance organization. Pharmacoepidemiology and Drug Safety, 2021, 30, 1576-1587.	0.9	3
64	Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKDâ€REIN cohort study. British Journal of Clinical Pharmacology, 2021, 87, 2967-2976.	1.1	17
65	Gastroesophageal Reflux Disease. JAMA - Journal of the American Medical Association, 2020, 324, 2536.	3.8	163
66	Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimerâ€™s disease. European Journal of Clinical Pharmacology, 2017, 73, 1149-1158.	0.8	8
67	Use of a proton pump inhibitor: Not more not less. Turkish Journal of Gastroenterology, 2019, 30, 504-504.	0.4	0
68	Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study. Korean Journal of Internal Medicine, 2020, 35, 1084-1093.	0.7	2
69	Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia: case review. International Journal of Physiology, Pathophysiology and Pharmacology, 2016, 8, 169-174.	0.8	11
70	Impact of Preventive Strategies on Gastrointestinal Complications in Elderly Patients on Concomitant Use of Oral Anticoagulants and Nonsteroidal Anti-Inflammatory Drugs: A Nationwide Cohort Study. Drug Safety, 2022, 45, 297-304.	1.4	2
71	AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology, 2022, 162, 1334-1342.	0.6	86
72	The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2022, 31, 370-378.	0.9	0

#	Article	IF	Citations
73	Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010â€“2018. European Journal of Clinical Pharmacology, 2022, 78, 657-667.	0.8	10
75	Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015. BMC Public Health, 2022, 22, 818.	1.2	16
76	Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study. BMC Nephrology, 2022, 23, 191.	0.8	3
77	The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis. Disease Markers, 2022, 2022, 1-9.	0.6	3
78	Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults. Atherosclerosis, 2022, 358, 47-54.	0.4	3
79	Proton pump inhibitor deprescription: A rapid review. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
80	Study on Drug Utilization and Evaluation of Proton Pump Inhibitors in Surgery Unit of Tertiary Care Teaching Hospital. International Journal of Pharmaceutical Sciences Review and Research, 0, , 55-59.	0.1	0
81	Reduce unnecessary use of proton pump inhibitors. BMJ, The, 0, , e069211.	3.0	10
82	Many People Take Proton Pump Inhibitor Unnecessarily: Reflecting On Why to Consider Deprescribing. , 2022, 37, 600-602.		0
83	Population-based cohort study: proton pump inhibitor use during pregnancy in Sweden and the risk of maternal and neonatal adverse events. BMC Medicine, 2022, 20, .	2.3	6
84	Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort. Gut Pathogens, 2022, 14, .	1.6	4
85	Trends in prescribing volumes and costs of proton pump inhibitors in three outpatient specialties: a three-year retrospective study in a tertiary hospital in Thailand. International Journal of Pharmacy Practice, 2023, 31, 80-85.	0.3	2
86	Proton Pump Inhibitor Use Before and After a Diagnosis of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2023, 29, 1871-1878.	0.9	3
87	No evidence for the benefit of PPIs in the treatment of acute pancreatitis: a systematic review and meta-analysis. Scientific Reports, 2023, 13, .	1.6	0
88	Knowledge, attitude, and practices regarding proton pump inhibitors among community pharmacists and pharmacy students. Nigerian Journal of Clinical Practice, 2023, 26, 201.	0.2	2
89	Physicians' views on pharmacists' involvement in hospital deprescribing: A qualitative study on proton pump inhibitors. Basic and Clinical Pharmacology and Toxicology, 2023, 133, 718-728.	1.2	2
92	Proton pump inhibitor use: systematic review of global trends and practices. European Journal of Clinical Pharmacology, 2023, 79, 1159-1172.	0.8	11